Jon Amund Kyte | Head of Department for Clinical Cancer Research
University of Oslo, Oslo University Hospital

Jon A Kyte has combined expertise as clinical oncologist and immunotherapy researcher and is Head of the Department for Clinical Cancer Research, Oslo University Hospital (OUS), and Professor at Faculty of Medicine University of Oslo (UiO). Kyte is also Research Group Leader at Department Cancer Immunology, OUS/UiO, and leads the Institutional Review Bord for Oncology and the Institutional Research and Protocol Board for Advanced Cell Therapies. The Department for Clinical Cancer Research (www.cancertrials.no) harbours an Early-Phase Trial Unit, a Clinical Trial Office and Study Nurse Unit, and currently conducts ~80 clinical trials. Dr. Kyte did his PhD on cancer vaccines and training for oncologist at OUS, followed by a postdoc in T cell therapy with Dr. Pule at University College London. Kyte has experience as breast cancer consultant and is currently a consultant at the Early-Phase Trial Unit conducting trials across solid cancers. Kyte has initiated and conducted several clinical trials combining immunological checkpoint inhibitors with chemotherapy or radiotherapy. The Kyte research group («Immunotherapy Against Solid Cancers»; www.ous-research.no/kyte) conducts laboratory research based on material from immunotherapy trials, aimed at personalising treatment. Further, the group develops tumor-targeting chimeric antigen receptors (CARs) for cell therapy against solid cancers, as well as strategies designed to make the CAR T cells resistant to immune suppression. Kyte is also a professor at the UiO Growth House (University Innovation Hub; www.uio.no/english/research/interfaculty-research-areas/growth-house) and a co-founder of the spin-out company ImmunoQuest Therapeutics (Immunoqt.com), which was established based on innovations from the Kyte Research Group.